Bristol-Myers Squibb Co. announced first results from the Opdivo (nivolumab) plus Yervoy (ipilimumab) cohort of the phase I/II CheckMate-040 study, evaluating the immuno-oncology combination in patients with advanced hepatocellular carcinoma previously treated with sorafenib.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
